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A  speciﬁc  peptide  marker  for  diagnosing  rheumatoid  arthritis  (RA)  was  found  based  on cyclic  citrulli-
nated  peptide  (CCP)  using  the  following  three  steps:  (1)  analysis  of the  binding  epitope  of autoimmune
antibodies  using  -aminocaproic  acid-modiﬁed  peptides;  (2)  RA diagnosis  using  sequence-modiﬁed  pep-
tides; and  (3)  evaluation  of  the  peptides’  diagnostic  performance  for  RA  diagnosis.  Ninety-ﬁve  serum
samples  were  analyzed  by  ELISA  and  compared  using  MedCalc  (version  15.2.1).  Microplate  binding  -
aminocaproic  acid  was  added  to  the N-  or C-terminal  of the  CCP  sequence.  The  N-terminal  anchoring
peptide  assay  showed  15% higher  speciﬁcity  compared  with  the C-terminal  anchoring  peptide assay.
Based  on this  result,  the  hydrophilic  C-terminal  sequence  of  CCP  was  substituted  with  a  hydrophobic
amino  acid.  Among  the sequence-modiﬁed  peptides,  CCP11A  (in  which  alanine  was  substituted  for  the-aminocaproic acid
equence modiﬁcation
iagnostic marker
11th  amino  acid  of  CCP)  assay  showed  the  highest  sensitivity  (87%)  and  speciﬁcity  (100%)  for  RA diagnosis.
Thus,  CCP11A  was  selected  as a possible  speciﬁc  marker  peptide  for RA  diagnosis  and  further  analyzed.
The  results  of  this  analysis  indicated  that  CCP11A  showed  better  speciﬁcity  than  the  CCP  assay  in  both
healthy  individuals  (11%  better)  and  OA  cohort  (20%  better).  From  these  results,  CCP11A  was  evaluated
as  a speciﬁc  marker  for diagnosing  RA with  higher  diagnostic  performance.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease
f uncertain etiology. In RA patients, the synovium in the joint
ecomes inﬂamed due to an autoimmune reaction, and this chronic
nﬂammation causes severe pain and work disability [1–6]. Growth
f the inﬂamed synovium from chronic inﬂammation deforms
he patient’s joint or bone and leads to impaired activity [7,8].
urrently, there are no drugs or treatments to aid the complete
ecovery from RA. Late diagnosis of RA leads to deformed joints
nd even damage to other organs by invasion [9]. For these rea-
ons, early diagnosis of RA is very important, both for symptom
elief and for retarding disease progression. In addition, differen-
iating RA from other autoimmune diseases or types of arthritis
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is important. There are as many as 80 types of autoimmune dis-
eases. Systemic lupus erythematosus (SLE), multiple sclerosis, and
celiac sprue disease are the most representative autoimmune dis-
eases with similar symptoms [10–12]. The most common types of
arthritis are osteoarthritis (OA) and RA. In contrast with RA, OA is
a mechanical disorder involving degradation of cartilage [13]. This
degradation also causes pain and impaired activity [14]. The pri-
mary cause of OA is mechanical stress, whereas RA and SLE result
from an autoimmune reaction [15]. An accurate differential diag-
nosis of RA from these autoimmune diseases or arthritis is essential
for patient-speciﬁc treatment.
The rheumatoid factor (RF) and anti-cyclic citrullinated peptide
(CCP) tests are the most widely used blood tests for the diagno-
sis of RA. The sensitivity of the RF test has been reported to be
from 70% to 75% [16–18], and its speciﬁcity has been reported
to be between 80% and 85% [16,17]. However, the RF antibody is
reported not to be found in all RA patients [17–19]. Therefore, the
speciﬁcity of the RF test has been limited. CCP is a 15-mer peptide
including citrulline with a cyclic structure from disulﬁde bonding
between cysteine sequences at both the N- and C-terminals. This
peptide has been reported to bind with autoimmune antibodies in
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Table 1
Sequences of CCP and modiﬁed peptide.
Name Sequence of peptides Modiﬁcations
CCP HCHQESTXGRSRGCG 1X, C C
RF  EGLHNHY –
HSH15 HSHQESTXGRSRGSG 1X
ZZH17 ZZHSHQESTXGRSRGSG 1X, 2Z
HSH17 HSHQESTXGRSRGSGZZ 1X, 2Z
ZZH19 ZZHSHQESTXGRSRGSGZZ 1X, 4Z
CCP10P HCHQESTXGPSRGCG 1X, C C
CCP11A HCHQESTXGRARGCG 1X, C C
CCP12P HCHQESTXGRSPGCG 1X, C C
CCPPAP HCHQESTXGPAPGCG 1X, C C
X = citrulline, C–C = disulﬁde bonding (Cys–Cys), Z = -aminocaproic acid.
Table 2
Characteristics of patients.
Disease type Number of
patients
Age Sex (F/M)
Rheumatoid arthritis (RA) 30 51.2 (25–74) 22/8
Osteoarthritis (OA) 15 47.3 (20–75) 13/208 M. Park et al. / Journal of Pharmaceutica
A patients [16,20,21]. Citrulline is a post-translational modiﬁed
eptide derived by peptidylarginine deiminases (PAD) [22]. This
itrulline has been known to play an important role in the recogni-
ion of autoimmune antibodies in serum from RA patients [20]. The
nti-CCP test shows high speciﬁcity (between 88% and 99%), and its
ensitivity has been shown to range from 45% to 91% [18,20]. In case
f Korean patients, the sensitivity of anti-CCP test has been reported
etween 72.0% and 82.3%, and its speciﬁcity has been reported to
e from 92.0% to 96.0% [19,23,24]. The current disadvantage of the
nti-CCP test is its lower speciﬁcity for RA diagnosis compared to
ther arthritis or autoimmune diseases [16]. Thus, evaluation of
ew biomarker with higher medical utility is important to improve
he diagnosis of RA.
To improve the diagnosis of RA, lots of novel biomarkers were
ecently discovered such as autoantibodies including carbamy-
ated protein (CarP), PAD type 4 (PAD4), v raf murine sarcoma
iral oncogene homologue B1 (BRAF), and University Hasselt-
A. clone numbers (UH-RA. number) [25]. These biomarkers are
on-CCP derived biomarker so they can diagnose RA in CCP-
egative patients [25]. CarP contains homocitrulline which is
ost-translational modiﬁed amino acid derived by cyanate. The
ensitivity and speciﬁcity of anti-CarP IgG test was reported to be
4.9% and 97.0%, respectively [26]. The sensitivity of the PAD4 test
as been reported to be from 27.8% to 82.8%, and its speciﬁcity has
een reported to be between 54.5% and 100.0% [27]. In case of BRAF
10 and p25 test, the sensitivity has been reported to be 35% and
9%, and the speciﬁcity was 93.0% and 100.0%, respectively [28].
he UH-RA clones resulted in poor sensitivity (Max. 29.4%) whereas
he speciﬁcity was higher than 95% [29]. These biomarkers showed
igh speciﬁcity except PAD4-P28 (54.5%).
Currently, RA is primarily diagnosed by visual inspection, and
lood testing is used as an auxiliary method for comprehensive
nalysis. In 1987, the American college of rheumatology (ACR)
stablished standard classiﬁcation criteria, and new classiﬁcation
riteria were jointly published by the ACR and the European league
gainst rheumatism (EULAR) in 2010 [30,31]. The new classiﬁcation
riteria established a system where points are assigned between 0
nd 10 for four areas: joint involvement, serologic parameters of
he RF and anti-CCP tests, acute phase reactants, and the duration
f arthritis. Among these four areas, half of the points are from joint
nvolvement analyzed by visual inspection. The serologic parame-
ers from speciﬁc biomarkers occupy only 30% of the total points.
he high ratio of visual examination indicates that there is no spe-
iﬁc and reproducible serum biomarker for RA diagnosis.
For developing a more speciﬁc marker of RA, we modiﬁed CCP
y the addition of -aminocaproic acid for the analysis of binding
ites between CCP-based peptides and autoimmune antibodies in
erum from RA patients. The binding epitope of the autoimmune
ntibody was analyzed by ELISA using N-, C-, and both N- and C-
erminal anchoring peptides. Then, sequence-substituted peptides
ere designed according to the epitope analysis, and RA samples
ere tested using these peptides.
. Materials and methods
.1. Materials
Cyclic citrullinated peptide (CCP) and modiﬁed peptides were
ynthesized with purities of 95% by Peptron Co. (Daejeon, Korea).
he sequences of peptides are described in Table 1. Polyclonal
nti-human immunoglobulin G (IgG) antibodies conjugated with
orseradish peroxidase (HRP) were obtained from Abcam (Cam-
ridge, UK). The 3,3′,5,5′-tetramethylbenzidine (TMB) substrate
or HRP detection and a 96 well-microplate were purchased from
hermo Scientiﬁc (Rockford, IL, USA). Premade phosphate bufferedSystemic lupus erythematosus (SLE) 25 38.3 (22–83) 24/1
Healthy individuals 25 52.6 (29–76) 15/10
saline (PBS) was obtained from WelGene (Daejeon, Korea). Other
chemical reagents, including Tween-20 and bovine serum albumin
(BSA), were purchased from Sigma–Aldrich (St. Louis, MO, USA).
2.2. Serum collection
Thirty serum samples from patient with RA, diagnosed accord-
ing to the 2010 American rheumatism association (ARA) criteria,
were collected at Kang-Nam St. Mary’s Hospital [30]. Fifteen
osteoarthritis (OA) patients’ sera and 25 systemic lupus erythe-
matous (SLE) patients’ sera were obtained at Kang-Nam St. Mary’s
Hospital and Yonsei University College of Medicine, respectively.
Serum from 25 healthy individuals (HI) was collected at Korea Uni-
versity Guro Hospital. There were 22 female and 8 male RA patients,
and their mean age was  51.2 (range, 25–74) years. Patient infor-
mation (age, gender) is described in Table 2. All serum samples
from patients and HI were obtained according to the Declaration of
the Helsinki. The study was approved by the institutional review
board (IRB) of the Kang-Nam St. Mary’s Hospital, Yonsei University
College of Medicine, and Korea University Guro Hospital.
2.3. ELISA assay using CCP based peptides
The synthesized peptides were immobilized on a 96-well
microplate by adding 100 L of diluted solution in PBS with a
concentration of 10 g/mL. After overnight incubation at 4 ◦C, the
solution was  removed, and the non-binding site was  blocked with
10 mg/mL  BSA dissolved in PBS. After 1 h incubation at room tem-
perature (RT), the blocked microplate was washed three times
with 0.1% Tween-20 in PBS. For the autoimmune antibody detec-
tion, 100 L of a serum sample diluted with PBS (1:200) was
transferred into a well and incubated for 1 h at RT. After bind-
ing the autoimmune antibodies with the peptide, the microplate
was again washed three times with same solution. Then, 100 L of
HRP-conjugated anti-human IgG antibody (100 ng/mL in PBS) was
dispensed into each well for detection of autoimmune antibodies.
After 1 h incubation at RT, the microplate was washed three times,
and 100 L of TMB  substrate solution was treated at RT. After 5 min,
the reaction was  stopped by adding 100 L of 2 M sulfuric acid. The
optical density of the plate was measured at a 450-nm wavelength
by microplate reader (Bio-rad, Hercules, US). All experimental steps
were repeated three times.
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Table 3
Sensitivity and speciﬁcity of CCP and -aminocaproic acid modiﬁed peptide assays.
Peptide name Sensitivity (%) Speciﬁcity (%)
RF 80 81
CCP 93 89
HSH15 100 69
ZZH17 87 85Fig. 1. Schematic diagram of peptide immobilization
.4. Statistics
To compare means among the four different cohorts of patients,
ukey’s multiple comparison was used in this study. Signiﬁcant dif-
erences between HI and the disease cohort were calculated by
-test. The test was regarded as statistically signiﬁcant when the
btained p-value was less than 0.05. All analyses, including Tukey’s
ultiple comparison, sensitivity, speciﬁcity, receiver operating
urves (ROC), and areas under the curve (AUC) were calculated by
edCalc ver 15.2.1 (MedCalc Software, Mariakerke, Belgium). Sig-
iﬁcant differences among assays were calculated by the McNemar
est.
. Results and discussions
.1. Analysis of binding epitopes of autoimmune antibodies
For the evaluation of the binding site between biomarker pep-
ides and autoimmune antibodies in serum, RA patient serum was
nalyzed by ELISA using -aminocaproic acid modiﬁed peptides.
-aminocaproic acid has a hydrophobic n-pentyl group as its side
hain, so that was used as an anchor for peptide immobilization on
he microplate [32]. The CCP peptide was linearized by the modiﬁ-
ation of cysteine to serine, which results in the deletion of disulﬁde
onding (HSH15). Then, the other peptides were changed by adding
wo -aminocaproic acids to the N- (ZZH17), C- (HSH17), or both
he N- and C- (ZZH19) terminals of the linearized peptide, HSH15.
he sequence-modiﬁed peptides are described in Table 1, and Fig. 1
hows the different binding structure of one linearized peptide
nd three modiﬁed peptides. Using these modiﬁed peptides, direct
LISA was performed for sera of RA, OA, and SLE patients.
Fig. 2 shows the results of Tukey’s multiple comparison among
he three disease cohorts (RA, OA, and SLE) and the HI. Autoim-
une antibody levels from HI samples were signiﬁcantly lower
han those from disease samples in all assays (p < 0.001). The RF
ssay was less signiﬁcant between RA cohort and HI (p = 0.0002)
han that of CCP (p < 0.0001) and showed lower optical density (OD)
alues for RA cohort (0.2345) than for OA (0.2437) and SLE (0.2957)
ohorts. In the CCP assay, the OD value of RA cohort 2.9-fold higher
han that of HI (0.0874) and also higher than those for OA (0.2314)
nd SLE (0.2347) cohorts. For the diagnosis of RA, the citrullinated
equence in CCP plays a primary role [16]. The linearized peptide
HSH15) assay showed a lower OD value for RA cohort than for OA
nd SLE cohort, suggesting that the cyclic structure of CCP is essen-
ial for the exposure of citrulline toward autoimmune antibodies in
erum. In the -aminocaproic acid-modiﬁed peptides assays, differ-
nces between the patient cohorts and HI were highly signiﬁcantly
ifferent (p < 0.0001). ZZH19 has additional two -aminocaproic
cid sequences at both the N- and C-terminals so that the cen-
ral sequence, citrulline, is exposed by anchoring both the N- andHSH17 100 69
ZZH19 90 81
C- terminals on a microplate (Fig. 1). For this reason, the ZZH19
assay showed higher OD values for RA cohort (0.4008) than for OA
(0.3069) and SLE (0.3693) cohorts. The C-terminal anchored pep-
tide, the HSH17 assay, also showed a lower OD value for RA cohort
than for OA and SLE cohorts. In the case of the ZZH17 assay, the
N-terminal was  anchored on the microplate, and the C-terminal
sequences were exposed toward autoimmune. The ZZH17 assay
showed a higher OD value for RA cohort (0.2667) than for OA cohort
(0.2344). These results suggest that the C-terminal sequences of
CCP have a more speciﬁc afﬁnity with autoimmune antibodies in
RA patient’s serum.
The sensitivity and speciﬁcity of the CCP-based assays for RA
cohort were calculated (Table 3). The sensitivity and speciﬁcity
of the RF assay were 80 and 81%, respectively. The CCP assay
showed higher sensitivity (93%) and speciﬁcity (89%). The lin-
earized peptide (HSH15) assay showed 100% sensitivity, whereas
the speciﬁcity was much lower (20%) compared with that for
the CCP assay. It also supports that the cyclic structure of CCP is
essential for RA diagnosis. Among the three -aminocaproic acid-
modiﬁed peptides assays, the ZZH17 assay showed the highest
speciﬁcity (85%). The C-terminal anchoring peptide (HSH17) assay
showed 16% lower speciﬁcity (69%) compared with the ZZH17
assay. These results indicate that C-terminal sequences are more
signiﬁcant than are N-terminal sequences for the diagnosis of RA.
3.2. RA diagnosis using sequence-modiﬁed peptides
We further modiﬁed the C-terminal sequences of CCP between
citrulline and cysteine (GRSRG). Both arginine and serine are
hydrophilic amino acids, and therefore the sequences were sub-
stituted with hydrophobic proline and/or alanine to examine
differences in diagnostic performance. The sequences of the mod-
iﬁed peptides are described in Table 1 (CCP10P, CCP11A, CCP12P,
and CCPPAP), and these peptides were tested for their ability to
diagnose RA. As shown in Fig. 3, the OD values from the patient
cohorts were signiﬁcantly higher than those from HI in all assays
(p < 0.001). In the CCP assay, the OD value of RA cohort was  higher
than that for OA cohort (Fig. 2a). As shown in Fig. 3b, only the
CCP11A test showed an 11% higher OD value for RA cohort (0.3091)
compared with that for OA cohort (0.2689), whereas that of RA
110 M. Park et al. / Journal of Pharmaceutical and Biomedical Analysis 115 (2015) 107–113
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Sig. 2. ELISA assay of CCP and -aminocaproic acid-modiﬁed peptides. (*: p < 0.005,
sing  (a) RF, (b) CCP, (c) HSH15, (d) ZZH17, (e) HSH17, and (f) ZZH19 peptides.
ohort was lower than that of OA cohort for the CCP10P, CCP12P,
nd CCPPAP tests (Fig. 3). These results suggest that the diagnostic
erformance of test for RA can be improved by the substitution of
 hydrophilic 11th amino acid to hydrophobic alanine.
The sensitivity and speciﬁcity of ELISA using sequence-modiﬁed
eptides were calculated (Table 4). The results of these modiﬁed
eptides showed increased speciﬁcities, especially the CCP11A,
CP12P, and CCPPAP assays. In the case of the CCP10P assay, its
A speciﬁcity was lowest (77%) among the peptides, so it was
xcluded as an RA diagnostic marker. The RA speciﬁcities of the
CP11A, CCP12P, and CCPPAP assays were 100%. The sensitivities of
he CCP12P and CCPPAP assays were relatively lower (70% and 77%
espectively) than that for the CCP11A assay. Among those assays,
able 4
ensitivity and speciﬁcity of sequence modiﬁed peptide assays.
Peptide name Sensitivity (%) Speciﬁcity (%)
CCP10P 83 77
CCP11A 87 100
CCP12P 70 100
CCPPAP 77 100 0.001, ***: p < 0.0001). RA, OA, SLE, and healthy individuals (N) samples were tested
the CCP11A assay showed the highest sensitivity (87%) and speci-
ﬁcity (100%) for RA diagnosis. The sensitivity was 6% lower than
that of the CCP assay, whereas its speciﬁcity was  11% higher. The
sensitivity of anti-CCP test has been reported to be between 45%
and 91%, and its speciﬁcity has been reported to be from 88% to
99% [18–20]. Comparing with those results, CCP11A assay showed
high level of both sensitivity and speciﬁcity. From these results,
we selected CCP11A as a valuable speciﬁc marker peptide for RA
diagnosis.
3.3. Evaluation of CCP11A as a diagnostic marker for RA
As noted above, we selected CCP11A as a possible speciﬁc
peptide marker for RA diagnosis. The ELISA results were further
analyzed by MedCalc, and the obtained receiver operating char-
acteristic ROC curves of CCP, CCP10P, and CCP11A are shown in
Fig. 4. If the HI were regarded as negative controls, then the obtained
areas under the curve (AUCs) from the ROC curves were 0.97, 0.84,
and 0.98 for the CCP, CCP10P, and CCP11A assays, respectively. The
CCP11A assay showed a higher AUC than did the CCP assay, indi-
cating that CCP11A has better diagnostic performance compared
M. Park et al. / Journal of Pharmaceutical and Biomedical Analysis 115 (2015) 107–113 111
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CP10P,  (b) CCP11A, (c) CCP12P, and (d) CCPPAP peptides.
o CCP for differentiating RA from HI. For higher diagnostic perfor-
ance in RA, the differentiation of RA from other forms of arthritis
s required. For this analysis, OA cohort was regarded as the nega-
ive controls, and ROC curves were obtained. From the ROC curves,
he obtained AUCs were 0.61, 0.50, and 0.69 for CCP, CCP10P, and
CP11A, respectively. CCP11A also showed the highest AUC among
hem. Therefore, CCP11A had a higher diagnostic performance com-
ared to CCP and CCP10P, and we evaluated CCP11A as a speciﬁc
arker for differentiating RA from HI or OA cohort.
From the ROC curves, the calculated sensitivities and speci-
cities of diagnosing RA from OA are described in Fig. 5. The
ensitivities of CCP, CCP10P, and CCP11A were 70%, 30%, and 63%,
espectively, and the speciﬁcities were 60%, 93%, and 80%, respec-
ively. The speciﬁcity of CCP10P was the highest among those three
eptides. However the sensitivity was very poor (<30%), indicating
hat is not suitable as an RA diagnostic marker. The CCP11A assay
howed a 20.0% higher speciﬁcity and a 6.7% lower sensitivity than
he CCP assay, and it was further analyzed by the McNemar test. p = 0.0001). RA, OA, SLE, and healthy individuals (N) samples were tested using (a)
When the OA cohort was  regarded as negative controls, the CCP and
CCP10P assays showed a 38% difference (p = 0.004), and the CCP10A
and CCP11A assays showed a 27% difference (p = 0.04). These data
indicate that the CCP10P assay was  signiﬁcantly different from
both the CCP and CCP11A assays, with poor diagnostic performance
based on its low sensitivity (30%). Therefore, the hydrophilic 10th
amino acid sequence of CCP plays an important role, and sub-
stitution of this sequence to a hydrophobic proline decreases its
performance as a diagnostic marker for RA. It further suggests that
this 10th amino acid sequence should not be substituted so that
it will remain hydrophilic for an RA diagnostic marker. The differ-
ence between the CCP and CCP11A was 11% (p = 0.18), indicating
that the positive and negative prediction rates for the CCP and
CCP11A assays are statistically similar. However, CCP11A showed
an 11% or 20% higher speciﬁcity than did the CCP assay when com-
pared with HI or OA cohort, respectively. Therefore, CCP11A could
be utilized as an improved speciﬁc marker for differentiating RA
from HI or OA cohort without a signiﬁcant difference from the CCP
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esult. When the SLE cohort was regarded as negative control, both
CP and CCP11A assays showed poor speciﬁcity less than 40% (data
ot shown). This poor speciﬁcity means that CCP-based assay has
imitation to diagnosis among the autoimmune disease. The posi-
ive percentage of RA patients who were predicted as negative by
CP has been reported to be from 16% to 50% using BRAF and CarP
25,26,28,33]. To improve the speciﬁcity from other autoimmune
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ig. 5. Sensitivity and speciﬁcity of the CCP, CCP10P, and CCP11A tests. RA cohort
as  compared with OA cohort. n.s. = not signiﬁcant.s compared with healthy individuals by (a) CCP, (b) CCP10P, and (c) CCP11A tests
diseases, combination of CCP11A with those biomarkers should be
useful for RA diagnosis.
4. Conclusion
The binding site of the autoimmune antibody in RA patient
serum was evaluated using an -aminocaproic acid-modiﬁcation
of CCP. From our results, the C-terminal sequences of CCP were
conﬁrmed to have more speciﬁc afﬁnity with autoimmune anti-
bodies, and the cyclic structure of CCP was  shown to be essential
for RA diagnosis. When the sequence of CCP was substituted with
a hydrophobic amino acid, the substitution of the 10th amino acid
decreased RA diagnostic performance and substitution of the 11th
amino acid improved speciﬁcity. Thus, CCP11A was  evaluated as a
speciﬁc marker for diagnosing RA with higher diagnostic perfor-
mance than CCP. Despite its improved speciﬁcity, the CCP-based
marker is limited in its speciﬁcity for differentiating RA from other
autoimmune diseases. Until now, the immunogenicity of the anti-
CCP antibody has not been reported. The discovery of its exact
immunogenicity would greatly improve the evaluation of more
speciﬁc biomarkers for early diagnosis of RA.
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